Two adoptive cell therapy approaches for solid tumors and epithelial cancers have received FDA approval (Iovance Biopharmaceutical’s AMTAGVI(R) and Adaptimmune’s TECELRA(R)) and many more under clinical development are showing promise. G-Rex has long been the gold standard in the research, development, and manufacturing of these innovation approaches.
G-Rex & TCR-T cell therapy
TCR-T cell therapy leaders choose G-Rex
Listen to Dr. Cassian Yee from M.D. Anderson Cancer Center (an early adopter of G-Rex) give a masterclass on how TCR-T cell therapy brings hope to cancer patients.
G-Rex & Tumor Infiltrating Lymphocyte (TIL) therapy
TIL therapy leaders choose G-Rex
One of the most pivotal moments in the G-Rex’s history was the adoption and implementation of G-Rex at the National Cancer Institute’s Surgery Branch, led by the legendary Dr. Steven A Rosenberg.
The NCI Surgery Branch continues to utilize G-Rex to this today for their various adoptive cell therapy programs to bring hope to solid tumor cancer patients.
Listen to Dr. Marie-Andree Forget from CTMC chronicle the co-evolution of TIL therapy and G-Rex.
G-Rex & Tumor-Associated Antigen (TAA) T cell therapy
T cell therapy leaders choose G-Rex
Listen to Dr. Ann Leen from the Baylor College of Medicine describe a recent breakthrough in pancreatic cancer through the use of a polyclonal T cell product, powered by G-Rex.